Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for prevention of postoperative endoscopic recurrence in Crohn's disease
2017-002258-36Phase 2Terminated
- Sponsor
- Alfasigma
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Rifaximin delayed-release with Placebo (2 arms). Primary endpoint: Endoscopic recurrence at 26 weeks. Started Aug 2017; status: terminated.
02
Drugs
rifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-002258-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002258-36.